Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: A Phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 3, 1997, Pages 230-232

  Nardi, M ^a   Aloe, A ^a   De Marco, S ^a   Cognetti, F ^a   Iacovelli, A ^a   Atlante, G ^a   Calabresi, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Ovarian cancer; Paclitaxel; Salvage therapy

Indexed keywords

NEW DRUG; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; MYOSITIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; VOMITING;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 0030941837     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199706000-00003     Document Type: Article

References (5)

1. Stanhope CR, Smith JP, Rutledge FN. Second trial drugs in ovarian cancer. Gynecol Oncol 1977;5:52.
2. McGuire WP, Rowinsky EK, Rosenhein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
3. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecological Oncology Group study. J Clin Oncol 1994;12:1748-53.
4. Einzig Al, Wiernick PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-53.
5. Kohn E, Reed E. Controversies in the treatment of advanced ovarian cancer. NIH Catalyst 1994;May:17-22.